KPV vs LL-37
Reviewed by the BestHealingPeptides Editorial Team ·
KPV and LL-37 occupy overlapping but distinct niches in the inflammation–antimicrobial peptide space. KPV is small, charge-neutral, and primarily anti-inflammatory; LL-37 is larger, cationic, and combines direct antimicrobial activity with broad immunomodulation.
KPV
A three-amino-acid C-terminal fragment of α-MSH studied for its anti-inflammatory effects in colitis, atopic skin conditions, and mucosal healing models — without the pigmentary effects of full-length MSH.
LL-37
The only human cathelicidin antimicrobial peptide — a 37-residue cationic amphipathic helix studied for direct antimicrobial action, wound healing, angiogenesis, and dual-edged modulation of host innate immune responses.
| Aspect | KPV | LL-37 |
|---|---|---|
| Size | 3 residues (~342 Da) | 37 residues (~4.5 kDa) |
| Mechanism | Intracellular NF-κB pathway suppression | Cationic membrane disruption + FPR2/EGFR signalling |
| Principal research area | Gut + skin anti-inflammatory | Antimicrobial + wound re-epithelialisation |
| Notable risk | Rapid GI degradation — typically encapsulated for oral | Elevated levels implicated in psoriasis / rosacea (double-edged) |
| Pigmentary activity | None (lacks α-MSH N-terminal sequence) | Not relevant |
| WADA status | Not listed | Not listed |
Size and chemistry
KPV is a 3-residue tripeptide (Lys-Pro-Val, 342 Da) with net-neutral to modestly cationic charge and minimal immunogenicity risk given the small size. It lacks any pigmentary N-terminal α-MSH sequence, so the peptide does not engage melanocortin receptors. LL-37 is a 37-residue amphipathic alpha-helix (~4.5 kDa) with substantial secondary structure — disordered in aqueous solution, refolding into an alpha-helix at anionic lipid membrane surfaces. Its high net positive charge (+6 at physiological pH) and amphipathic architecture drive both its antimicrobial membrane-disruption activity and its extensive plastic adsorption in labware. The size and charge differences translate to substantially different formulation and handling requirements between the two compounds.
Mechanism
KPV principally suppresses NF-κB-driven cytokine transcription through intracellular pathway modulation independent of melanocortin-receptor engagement. It gains cellular entry through the PepT1 (SLC15A1) di/tripeptide transporter, which is upregulated in inflamed intestinal mucosa — providing a mechanistic explanation for its preferential activity at inflamed rather than healthy tissue. Downstream, NF-κB p65 nuclear translocation is reduced with parallel decreases in TNF-α, IL-1β, and IL-6 transcription. LL-37 disrupts anionic microbial membranes directly through its cationic amphipathic helix architecture (carpet-model membrane permeabilisation, toroidal-pore formation) and additionally activates formyl peptide receptor 2 (FPR2/ALX) on immune cells and endothelium, transactivates EGFR on keratinocytes through ADAM-10/17-mediated HB-EGF shedding, and drives angiogenesis. The dual antimicrobial-plus-signalling profile distinguishes it from purely bactericidal agents.
Evidence base
KPV has a focused, mechanistically consistent pre-clinical literature in DSS- and TNBS-induced colitis models, atopic dermatitis cell-culture work, and other NF-κB-driven inflammation contexts. The Laroui 2013 hyaluronic-acid nanoparticle encapsulation work transformed oral KPV from near-zero exposure to therapeutically relevant colonic concentrations. LL-37 has a much broader literature spanning direct antimicrobial defence (MIC 2-8 µg/mL against MRSA, 4-16 µg/mL against Pseudomonas), wound healing and re-epithelialisation, angiogenesis, and — importantly — the double-edged autoinflammatory role in psoriasis, where LL-37/self-DNA complexes activate plasmacytoid dendritic cell TLR9 to drive IFN-α release (Lande, Nature 2007). The autoinflammatory dimension is unique to LL-37 among cationic antimicrobial peptides.
Safety and formulation considerations
KPV's small size and lack of pigmentary activity contribute to a clean safety reputation in research. Standard bacteriostatic water reconstitution and 28-day refrigerated storage apply; no special labware requirements. LL-37 requires more careful handling: its high cationicity causes substantial adsorption to standard polystyrene and polypropylene surfaces, so nominal-versus-effective concentrations can diverge markedly. Low-binding vessels and carrier-protein supplementation (BSA at 0.01-0.1%) are recommended. Serum proteins (alpha-2-macroglobulin, LDL, heparan sulphate proteoglycans) bind LL-37 avidly, reducing free effective concentration in serum-containing media — MIC assays are conventionally conducted in serum-free conditions. Elevated local LL-37 concentrations are implicated in psoriasis and rosacea, a consideration for chronic-exposure research protocols.
Choosing between them
Choose KPV for gut/mucosal anti-inflammatory research where NF-κB-driven cytokine cascade suppression is the mechanistic hypothesis — colitis models, atopic dermatitis, non-microbial inflammation. Choose LL-37 where antimicrobial or membrane-disruptive properties are the research target — chronic wound infection, biofilm disruption, host-defence signalling. The two are mechanistically complementary rather than interchangeable, and combined use in mucosal defence protocols is a legitimate research design where both innate antimicrobial defence and downstream inflammatory-cytokine suppression are relevant to the pathology being studied.
Verdict
Choose KPV for gut/mucosal anti-inflammatory work where NF-κB pathway suppression is the mechanistic hypothesis, and LL-37 where antimicrobial or membrane-disruptive properties are the research target. They are mechanistically complementary rather than interchangeable — combined use across the antimicrobial-plus-anti-inflammatory axis is a legitimate research design in mucosal-defence protocols.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.